Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Vall D Hebron Institute Of Oncology
Sponsor

Vall D Hebron Institute Of Oncology

Spain Calle Natzaret 115, 08035 Barcelona, Spain

About the sponsor

Research activity includes metastatic colorectal cancer, BRAF V600E-mutant mCRC, microsatellite stable and microsatellite instable colorectal disease, as well as gastric cancer and gastroesophageal junction cancer.

  • BRAF-targeted treatment strategies
  • Rechallenge approaches in metastatic disease
  • Neoadjuvant treatment for gastric and GEJ cancer
  • Colorectal and endometrial tumors with mismatch repair features

The portfolio also covers antibody-based and immune-based combinations in advanced digestive tract malignancies.

About Specializations

Vall D Hebron Institute Of Oncology runs clinical trials in conditions such as Colorectal cancer metastatic, Gastric cancer, BRAF V600E mutation positive, Neoplasm, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

12 clinical trials

Colorectal cancer metastatic+1

Recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Encorafenib
  • Sponsor:Vall D Hebron Institute Of Oncology

Neoplasm+2

Recruiting
Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Vall D Hebron Institute Of Oncology

Neoplasm malignant

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Vall D Hebron Institute Of Oncology

Gastric cancer+1

Recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Endometrial cancer+3

Recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Colorectal cancer metastatic

Recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Adrenocortical carcinoma

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Amsterdam UMC Stichting

Gastric cancer

Not yet recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Clear cell renal cell carcinoma

Not yet recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Vall D Hebron Institute Of Oncology

Osteosarcoma metastatic

Not yet recruiting
Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Omo-103
  • Sponsor:Vall D Hebron Institute Of Oncology

Endometrial cancer recurrent

Not recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Vall D Hebron Institute Of Oncology

Colorectal cancer metastatic+1

Not recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).